期刊文献+

胰腺癌免疫治疗研究现状 被引量:1

下载PDF
导出
摘要 胰腺癌是目前消化系统恶性肿瘤中恶性程度较高的一种,生存率极低,外科手术是目前唯一比较理想的治疗方法。但据统计,只有约10%的患者可行手术治疗,即使是行根治性胰十二指肠切除术的患者术后复发也很常见.且胰腺癌对放射治疗(放疗)、化学治疗(化疗)敏感性均低。据报道根治术后再辅以化疗患者的5年生存率〈5%。因此,研究胰腺癌手术治疗之外的治疗方法十分重要.包括免疫治疗、基因治疗、抗血管生成治疗等。近年来针对胰腺癌免疫治疗方面有大量报道,我们总结了相关研究成果,就其作一综述。
作者 巩超捷 夏璐
出处 《内科理论与实践》 2008年第3期199-202,共4页 Journal of Internal Medicine Concepts & Practice
  • 相关文献

参考文献34

  • 1Jemal A;Thomas A;Murray T.Cancer statistics,2002,2002(01).
  • 2Dornh(o)fer N;Spong S;Bennewith K.Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis[J],2006(11).
  • 3Kindler HL;Friberg G;Stadler WM.Bevacizumab (B)plus gemcitabine(G)in patient(pts)with advanced pancreatic cancer(PC):updated results of a multi-center phase Ⅱ trial,2004(z14).
  • 4Cascinu S;Berardi R;Labianca R.Cetuximab plus gemeitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer:a randomised,muhicentre,phase Ⅱ trial,2008(01).
  • 5Eisold S;Schmidt J;Ryschich E.Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma[J],2007(01).
  • 6JingWang Xiao-XuanLu Dao-ZhenChen Shu-FengLi Li-ShanZhang.Herpes simplex vires thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer[J].World Journal of Gastroenterology,2004,10(3):400-403. 被引量:16
  • 7Bharadwaj U;Li M;Zhang R.Elevated interleukin-6 and G-CSF in human pancreatic cancer cell condi-tioned medium suDpress dendritic cell differentiation and activation[J],2007(11).
  • 8Hassan R;Ho M.Mesothelin targeted cancer immuno-therapy[J],2008(01).
  • 9Chang CL;Wu TC;Hung CF.Control of human mesothe-lin-expressing tumom by DNA vaccines[J],2007(16).
  • 10Zhu K;Qin H;Cha SC.Survivin DNA vaccine ge-nerated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models[J],2007(46).

二级参考文献35

  • 1AShankar,RCGRussell.Recent advances in the surgical treatment of pancreatic cancer[J].World Journal of Gastroenterology,2001,7(5):622-626. 被引量:19
  • 2Chang-Tai Xu~1 Lian-Tian Huang~1 Bo-Rong Pan~2 1 Editorial Department,the Journal of Fourth Military Medical University2 Oncology Center,Xijing Hospital,Fourth Military Medical University,169 Changle Xilu,Xi’an 710032,Shaanxi Province,China.Current gene therapy for stomach carcinoma[J].World Journal of Gastroenterology,2001,7(6):752-759. 被引量:16
  • 3夏忠军,常建华,张力,姜文奇,管忠震,刘基巍,张阳,胡晓桦,吴国华,王华庆,陈正常,陈建超,周清华,陆建伟,樊青霞,黄建瑾,郑晓.基因工程腺病毒(H101)瘤内注射联合化疗治疗头颈部及食管鳞癌的Ⅲ期临床研究[J].癌症,2004,23(12):1666-1670. 被引量:50
  • 4谭广,王忠裕,殷朔.白细胞介素-23基因修饰树突细胞获取凋亡癌细胞抗原诱导的抗胰腺癌免疫治疗[J].中华医学杂志,2006,86(14):943-946. 被引量:5
  • 5Cao X, ZhangW, Wang J, etal. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocytemaerophage colony stimulating factor genetically modified dendritie cells [J]. Immunology, 1999; 97(4):616
  • 6lnaba K, lnaba M, Romani N, et al. Generation of large numbers of dendritic eells from mouse bone marrow cultures supplemcnted with granuloeyte/maerophage colony stimulating factor[J]. J Exp Med, 1992; 176(6):1693
  • 7Celia M, Seheidegger D, Palmer Lehmann K, et al. Ligafion of CD40 on dendritic cells triggers production of high levels of interleukin 12 and enhances T cell stimulatory capacity: T-T help viaAPC activation[J]. J Exp Med, 1,996; 184(2):747
  • 8Wang YQ, Ugai S, Shimozato O, et al. Induction of systemic immunity by expression of interleukin-23 in murine colon eareinoma cells [J]. Int J Cancer, 2003: 105(6):820
  • 9Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor [J]. J Exp Med,1992,176(6):1693-1702.
  • 10Induction of systemic and therapeutic anti-tumor immunity using intratumor injection of dendritic cells genetically modified to express Interleukin 12[J]. Cancer Research, 1999, 59:4035-4041.

共引文献47

同被引文献27

  • 1刘钊.胰腺癌基因治疗研究进展[J].海南医学,2007,18(2):92-94. 被引量:1
  • 2张剑军(综述),刘鲁明(审校).胰腺癌免疫治疗进展[J].国际肿瘤学杂志,2007,34(1):58-61. 被引量:3
  • 3王彬,李槐.胰腺癌的综合治疗[J].中国介入影像与治疗学,2007,4(2):154-158. 被引量:9
  • 4Alexakis N,Halloran C,Raraty M,et al.Current standards of surgery for pancreatic cancer[J].Br J Surg,2004,91 (11):1410-1427.
  • 5Makowiec F,Post S,Saeger HD,et al.Current practice patterns in pancreatic suegery:result of a multi-institutional analysis of seven large surgical departments in Germany with 1454 pancreatic head resections,1999 to 2004 (German Advanced Surgical Treatment Study Group)[J].Journal of Gastrointest Surgerg,2005,9 (8):1080-1 087.
  • 6Farnell MB,Pearson RK,Sarr MG,et al.A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in respectable pancreatic head adenocarcinoma[J].Surgery,2005,138 (4):618-628.
  • 7Burris HA,Moore MJ,Anderson J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15:2 403-2 413.
  • 8Stomiolo AM,Enas NH,Brown CA,et al.An investigational new durg treatment program for patients with gemcitabine:result for over 3 000 petients with pancreatic carcinoma[J].Cancer,1999,85 (6):1 261-1 268.
  • 9黄强 翟仁友.中晚期胰腺癌的介入治疗.中国介入放射学,2008,2(1):77-82.
  • 10Edgar Ben Josef,Anthony F,Shields,et al.Intensity-Modulated adiotherapy(IMRT) And Concurrent Capecitabine For Pancreatic Cancer[J].Int Radiat Oncolbiolphys,2004,59(2):454-459.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部